Figure 4.

Implantable cancer vaccine. This technology consists of a biodegradable polymer scaffold containing cytokines, immune adjuvants, and antigen components from each patient's tumor. It is implanted subcutaneously at a site distant from the tumor, and works by recruiting dendritic cells and reprogramming the immune system to kill the cancer cells. The cancer vaccine is currently in Phase I human clinical trials and this general approach one day also could help overcome infectious diseases and auto‐immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. [Work from David Mooney and the Wyss Immuno‐Materials Platform]12